Implications for body weight extremes in solid organ transplantation
Abstract The pharmacokinetic profiles of medications are altered in overweight and underweight patients, but few studies have described these differences in patients with body mass index extremes. As solid organ transplant programs expand their candidate selection criteria to accommodate a growing population of patients with weight extremes, it has become imperative to understand and evaluate the impact weight extremes have on the pharmacokinetics of life‐sustaining immunosuppression in this population. This review will describe pharmacokinetic and dosing considerations for weight extremes in solid organ transplant recipients, including changes following bariatric surgeries, non‐pharmacologic and pharmacologic management strategies for weight loss and gain, and potential drug‐drug interactions with popular weight management products..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:41 |
|---|---|
| Enthalten in: |
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - 41(2021), 1, Seite 44-58 |
| Beteiligte Personen: |
Campara, Maya [VerfasserIn] |
|---|
| BKL: |
|---|
| Anmerkungen: |
© 2021 Pharmacotherapy Publications, Inc. |
|---|
| Umfang: |
15 |
|---|
| doi: |
10.1002/phar.2493 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
WLY012273864 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | WLY012273864 | ||
| 003 | DE-627 | ||
| 005 | 20230307235531.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230219s2021 xx |||||o 00| ||und c | ||
| 024 | 7 | |a 10.1002/phar.2493 |2 doi | |
| 028 | 5 | 2 | |a PHAR_PHAR2493.xml |
| 035 | |a (DE-627)WLY012273864 | ||
| 035 | |a (WILEY)PHAR2493 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 082 | 0 | 4 | |a 610 |q ASE |
| 084 | |a 44.40 |2 bkl | ||
| 084 | |a 44.38 |2 bkl | ||
| 100 | 1 | |a Campara, Maya |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Implications for body weight extremes in solid organ transplantation |
| 264 | 1 | |c 2021 | |
| 300 | |a 15 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © 2021 Pharmacotherapy Publications, Inc. | ||
| 520 | |a Abstract The pharmacokinetic profiles of medications are altered in overweight and underweight patients, but few studies have described these differences in patients with body mass index extremes. As solid organ transplant programs expand their candidate selection criteria to accommodate a growing population of patients with weight extremes, it has become imperative to understand and evaluate the impact weight extremes have on the pharmacokinetics of life‐sustaining immunosuppression in this population. This review will describe pharmacokinetic and dosing considerations for weight extremes in solid organ transplant recipients, including changes following bariatric surgeries, non‐pharmacologic and pharmacologic management strategies for weight loss and gain, and potential drug‐drug interactions with popular weight management products. | ||
| 700 | 1 | |a Lourenco, Laura M. |4 aut | |
| 700 | 1 | |a Melaragno, Jennifer I. |4 aut | |
| 700 | 1 | |a Kaiser, Tiffany E. |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy |g 41(2021), 1, Seite 44-58 |w (DE-627)WLY01227206X |x 18759114 |7 nnns |
| 773 | 1 | 8 | |g volume:41 |g year:2021 |g number:1 |g pages:44-58 |g extent:15 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_WLY | ||
| 912 | |a SSG-OPC-PHA | ||
| 912 | |a SSG-OPC-ASE | ||
| 936 | b | k | |a 44.40 |q ASE |
| 936 | b | k | |a 44.38 |q ASE |
| 951 | |a AR | ||
| 952 | |d 41 |j 2021 |e 1 |h 44-58 |g 15 | ||